World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
132
Citations
61985
World Ranking
2323
National Ranking
1313

Mark Raffeld publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Mark Raffeld sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 534 publications — 63rd percentile

63% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Mark Raffeld D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Mark Raffeld sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 132 D-Index — 89th percentile

89% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Mark Raffeld is a researcher affiliated with the National Institutes of Health in the United States. Their body of work spans primarily the fields of Medicine and Biochemistry, Genetics, and Molecular Biology, with a significant number of publications related to genetics, oncology, molecular biology, pathology and forensic medicine, and immunology.

The scientist's recent publications illustrate engagement with various topics in cancer biology and diagnostics. These include investigations into biomarkers, tumor heterogeneity, and immune recognition of neoantigens. Notable recent studies include:

  • MGMT Status as a Clinical Biomarker in Glioblastoma, 2020, published in Trends in Cancer
  • Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer, 2020, published in Cell Reports Medicine
  • Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens, 2020, published in Clinical Cancer Research
  • Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia, 2020, published in Journal of Clinical Oncology
  • Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics, 2021, published in Neuro-Oncology

Frequently collaborating with other researchers, Mark Raffeld has coauthored extensively with individuals including Liqiang Xi, Stefania Pittaluga, Kenneth Aldape, Svetlana Pack, and Hao-Wei Wang. These collaborations indicate an interdisciplinary and multi-institutional approach to scientific research.

Their work has been distributed across various publication venues, with the most frequent being:

  • The American Journal of Surgical Pathology (7 publications)
  • Journal of Clinical Oncology (6 publications)
  • Blood (6 publications)
  • Acta Neuropathologica (5 publications)
  • Clinical Cancer Research (3 publications)

Mark Raffeld's research covers a range of topics, with a focus on both diagnostic and treatment-related aspects of oncology and hematology. Some main topics of their work include:

  • Lymphoma Diagnosis and Treatment
  • Glioma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Viral-associated Cancers and Disorders
  • Cancer Genomics and Diagnostics
  • Cutaneous Lymphoproliferative Disorders Research
  • Neuroblastoma Research and Treatments

The diverse subfields and topics linked with their research demonstrate a broad expertise oriented toward cancer biology, diagnostics, and immunological aspects of tumor development and treatment.

Best Publications

  • Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

    Mark E. Dudley;John R. Wunderlich;Paul F. Robbins;James C. Yang

  • Gene-Expression Profiles in Hereditary Breast Cancer

    I Hedenfalk;D Duggan;Y Chen;M Radmacher

  • Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

    James N. Kochenderfer;Mark E. Dudley;Sadik H. Kassim;Robert P.T. Somerville

  • Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

    Paul F. Robbins;Richard A. Morgan;Steven A. Feldman;James C. Yang

  • Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

    James N. Kochenderfer;Wyndham H. Wilson;John E. Janik;Mark E. Dudley

  • Activated STING in a Vascular and Pulmonary Syndrome

    Y. Liu;A.A. Jesus;B. Marrero;D. Yang

  • ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile

    Adrian Wiestner;Andreas Rosenwald;Todd S. Barry;George Wright

  • The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia

    Yair Herishanu;Patricia Pérez-Galán;Delong Liu;Angélique Biancotto

  • Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma

    Aarif Y. Khakoo;Aarif Y. Khakoo;Shibani Pati;Stasia A. Anderson;William Reid

  • A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

    Paul F. Robbins;Sadik H. Kassim;Thai Lan N. Tran;Jessica S. Crystal

  • Mantle-cell lymphoma.

    E Campo;M Raffeld;E S Jaffe

  • B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma

    Robert O. Carpenter;Moses O. Evbuomwan;Stefania Pittaluga;Jeremy J. Rose

  • Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome

    Amy P. Hsu;Elizabeth P. Sampaio;Javed Khan;Katherine R. Calvo

  • Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma

    Barbara Ensoli;Rita Gendelman;Phillip Markham;Valeria Fiorelli

  • Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer.

    R E Donahue;S W Kessler;D Bodine;K McDonagh

  • EBV positive mucocutaneous ulcer--a study of 26 cases associated with various sources of immunosuppression

    Stefan D Dojcinov;Girish Venkataraman;Mark Raffeld;Stefania Pittaluga

  • p53 mutation is associated with progression in follicular lymphomas

    Christian A. Sander;Takahiro Yano;Helen M. Clark;Cynthia Harris

  • Pulmonary Nontuberculous Mycobacterial Disease: Prospective Study of a Distinct Preexisting Syndrome

    Richard D. Kim;David E. Greenberg;Mary E. Ehrmantraut;Shireen V. Guide

  • Immuno-LCM: laser capture microdissection of immunostained frozen sections for mRNA analysis.

    Falko Fend;Michael R. Emmert-Buck;Rodrigo Chuaqui;Kristina Cole

  • Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology

    Richard F. Little;Stefania Pittaluga;Nicole Grant;Seth M. Steinberg

Frequent Co-Authors

Elaine S. Jaffe
Elaine S. Jaffe National Institutes of Health
Stefania Pittaluga
Stefania Pittaluga National Institutes of Health
Maryalice Stetler-Stevenson
Maryalice Stetler-Stevenson National Institutes of Health
Seth M. Steinberg
Seth M. Steinberg National Institutes of Health
Wyndham H. Wilson
Wyndham H. Wilson National Institutes of Health
Svetlana Pack
Svetlana Pack National Institutes of Health
Robert J. Kreitman
Robert J. Kreitman National Cancer Institute
Leticia Quintanilla-Martinez
Leticia Quintanilla-Martinez University of Tübingen
Julie Teruya-Feldstein
Julie Teruya-Feldstein Icahn School of Medicine at Mount Sinai
Steven A. Rosenberg
Steven A. Rosenberg National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative online degrees can open up additional career options within the medical field. One popular option is a health care administration degree online, which prepares students for management roles in clinics, hospitals, and other healthcare organizations.

For those seeking to advance their careers, pursuing the cheapest master's in healthcare administration is a cost-effective way to gain specialized skills and qualify for leadership positions.

Nursing professionals aiming for the highest level of clinical practice may consider enrolling in one of the best online dnp programs. These programs equip nurses with advanced clinical skills and leadership training, often with flexible online options.

Aspiring pharmacists can also benefit from a 3-year online pharmd, allowing them to earn a Doctor of Pharmacy degree more quickly while balancing other commitments.

Whether you are interested in administration, advanced nursing, or pharmacy, online programs offer flexibility and affordability, supporting diverse career pathways in medicine.

Best Scientists Citing Mark Raffeld

Trending Scientists

Recently Published Articles